Zymeworks enters its first ZymeLink antibody-drug conjugate platform licensing agreement with Iconic Therapeutics

Image: ZymeLink antibody-drug conjugate (ADC) platform will be used to develop ICON-2 Tissue Factor ADC for cancer. Photo: courtesy of Colin Behrens / Pixabay.